- OpenAI releases reasoning AI with eye on safety, accuracy
- State judge strikes down North Dakota abortion ban
- No.1 Korda opens Solheim Cup for USA versus Hull and Henseleit
- Trump rules out new Harris debate as swing state fight resumes
- Bomb threat rattles US city in Republican anti-migrant conspiracy
- ECB rate cut boosts European stocks as Wall Street extends rally
- Alvarez aims to stop knockout artist Berlanga in latest title defence
- Business groups ask Ottawa to prevent Air Canada strike
- Cooler weather helps, but Los Angeles fires still out of control
- Macron, ex-PM remember bloody liberation of French port
- Noel Gallagher's 'Brit Pop' guitars go under hammer
- US clears way for hearing aid feature in new Apple AirPods Pro
- Hamilton not disappointed by Newey move to Aston Martin
- Final report clears WADA in Chinese swimmers case, adds rules need strengthening
- US calls for Africa to get two permanent UN Security Council seats
- Burrow's Bengals aim to bounce back against Chiefs
- Ingebrigtsen says getting stronger, bullish over world records
- Putin warns West risks 'war' if it backs Ukraine long-range strikes
- Peru mourns divisive former strongman Fujimori
- Vaughan's son takes 11 wickets as Somerset revive title bid by beating champions Surrey
- Long-awaited case on Man City charges to start on Monday: report
- PSG refuse League order to pay Mbappe disputed €55 million
- Harris, Trump target swing states after fierce debate
- Ten Hag hits back at Ronaldo criticism over Man Utd ambition
- Oscar hopefuls to bookend US French film festival
- UN chief calls for 'courage' ahead of Summit of the Future
- French rugby federation blames 'poorly managed' supervision for youth player drowning
- Movie producer Harvey Weinstein indicted on new charges: US media
- Ex-Scotland captain Hogg to miss Montpellier match after bail release
- 'Historic': Bad weather slashes wine harvest in France's Jura
- ECB rate cut boosts European stocks, euro
- Piastri not 'pulling over' for Norris at every race
- 'Energised' Tebogo looking to close season with Diamond League bang
- Millions in SE Asia battle floods, death toll passes 250
- Fiat 500 electric production pauses for one month
- London Fashion Week opens with Charli XCX party and second-hand runways
- ECB cuts rates again, Lagarde backs EU reform call
- Storm Francine downgraded but still drenching US south
- Everton say 'work to be done' on Textor takeover
- Shelling kills 3 Red Cross workers in E.Ukraine
- Shelling kills 3 Red Cross workers killed in E.Ukraine
- Iran president makes 'historic' visit to Iraqi Kurdistan
- Brigitte Macron awarded damages over false trans claim
- ECB rate cut boosts Europeans stocks, euro
- Deadly Israeli strike on Gaza school draws global condemnation
- Russia recaptures part of Kursk region
- Bike-loving Dutch grapple with 'fatbike' phenomena
- Ahead of Champions League warm-up, PSG are soaring and Brest slumping
- ECB cuts rates again as inflation slows
- Denmark's von Trier to direct a new film
EU approves Moderna's RSV vaccine for over 60s
The European Commission on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- the first time the bloc has authorised an mRNA shot against a disease other than Covid-19.
RSV is a highly contagious seasonal virus that can cause severe symptoms in infants and the elderly -- one in 20 of whom contract it each year in Europe, according to the European Centre for Disease Prevention and Control (ECDC).
In the European Union, Norway and United Kingdom, RSV leads to the hospitalisation of around 158,000 adults each year, as well as some 213,000 children under five, according to ECDC data.
"Vaccination saves lives," the EU's commissioner for health and food safety, Stella Kyriakides, said in a statement announcing the approval of Moderna's mResvia vaccine.
"We are determined to ensure that everyone has access to the protection that they need against serious diseases."
The authorisation, which follows a similar step by the US Food and Drug Administration in May, is based on a positive assessment by the European Medicines Agency (EMA) in June.
The EMA approved the use of mResvia for the prevention of lower respiratory tract disease (LRTD), which is caused by RSV, in adults of 60 and older.
The EU had previously approved two vaccines for protecting against RSV, manufactured by Pfizer and GSK.
GSK and Pfizer's vaccines rely on traditional technology: introducing a pathogen component to the immune system to trigger a response.
In contrast, Moderna's vaccine utilises cutting-edge messenger RNA (mRNA) technology, instructing the body to produce a unique protein that stimulates an immune response, teaching it to defend against the infection.
"This approval of the first mRNA vaccine against RSV clearly shows the importance of innovation when it comes to protecting the health of our citizens," Kyriakides said.
Stephane Bancel, Moderna's chief executive, said the commission's approval was "an important milestone for public health and highlights Moderna's mRNA leadership."
O.M.Souza--AMWN